MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2021.705096

Медицинская библиотека · Frontiers in immunology · 2021

Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.

Botticelli Andrea, Cirillo Alessio, Strigari Lidia, Valentini Filippo, Cerbelli Bruna, Scagnoli Simone, Cerbelli Edoardo, Zizzari Ilaria Grazia, Rocca Carlo Della, D'Amati Giulia, Polimeni Antonella, Nuti Marianna, Merlano Marco Carlo, Mezi Silvia, Marchetti Paolo

Сравнительное исследованиеСистематический обзорСтатьяNetwork Meta-AnalysisПеревод в очереди

Аннотация

OBJECTIVE

The monoclonal antibodies anti-programmed death protein-1 (anti-PD-1) nivolumab and pembrolizumab are the first immune checkpoint inhibitors (ICIs) approved for treatment of recurrent/metastatic head and neck carcinoma R/M HNSCC in first line and in platinum refractory disease. This network meta-analysis aims to investigate the efficacy of anti-PD-1- vs anti-PD-L1-based therapy in R/M HNSCC cancer patients through a systematic review of the literature to provide support for evidence-based treatment decisions. In particular, the effectiveness of ICIs for R/M HNSCC is analyzed according to the different mechanisms of action of the check-points inhibitory drugs in different subgroups of patients.

METHODS

We did a systematic literature review and network meta-analysis (NMA) of randomized controlled trials (RCTs) in PubMed, ClinicalTrials.gov, Embase, Medline, the Cochrane Central Register of Controlled Trials, Web of Science. Our search identified a total of five randomized controlled trials: Keynote 040, Keynote 048, Eagle, Condor, Checkmate 141. These trials included 3001 patients. Treatment was sub-categorized into PD-L1-based, PD-1-based, and standard chemotherapy. Treatments were indirectly compared with anti-PD-L1-based therapy.

RESULTS

The network meta-analysis demonstrated no significant differences in OS between different subgroups except for the metastatic patients in which anti-PD-1-based therapy was associated with significantly less risk of death. Furthermore, anti-PD-1-based therapy appeared to be effective in smoker patients and in human papilloma-negative (HPV) patients. Conversely, anti-PD-L1-based therapy seems to be better efficient in female patients, in locally recurrent setting and in HPV positive patients.

CONCLUSION

This is the first NMA study that aimed to indirectly compare anti-PD-1- and anti-PD-L1-based therapy in HNSCC patients. The results of our NMA could help define a profile of patient responder or resistant to specific classes of immune drugs and can be used to guide/design future studies in the novel scenario of precision immune-oncology.

Для цитирования: Botticelli Andrea, Cirillo Alessio, Strigari Lidia, Valentini Filippo, Cerbelli Bruna, Scagnoli Simone, Cerbelli Edoardo, Zizzari Ilaria Grazia, Rocca Carlo Della, D'Amati Giulia, Polimeni Antonella, Nuti Marianna, Merlano Marco Carlo, Mezi Silvia, Marchetti Paolo. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.. Frontiers in immunology. 2021. DOI: 10.3389/fimmu.2021.705096.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.